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Abstract
Background: We evaluated the long-term effect of stereotactic body radiation therapy (SBRT) for primary small
hepatocellular carcinoma (HCC) ineligible for local therapy or surgery.
Methods: Forty-two HCC patients with tumors ≤ 100 cc and ineligible for local ablation therapy or surgical
resection were treated with SBRT: 30-39 Gy with a prescription isodose range of 70-85% (median 80%) was
delivered daily in three fractions. Median tumor volume was 15.4 cc (3.0-81.8) and median follow-up duration 28.7
months (8.4-49.1).
Results: Complete response (CR) for the in-field lesion was initially achieved in 59.6% and partial response (PR) in
26.2% of patients. Hepatic out-of-field progression occurred in 18 patients (42.9%) and distant metastasis developed
in 12 (28.6%) patients. Overall in-field CR and overall CR were achieved in 59.6% and 33.3%, respectively. Overall 1-
year and 3-year survival rates were 92.9% and 58.6%, respectively. In-field progression-free survival at 1 and 3 years
was 72.0% and 67.5%, respectively. Patients with smaller tumor had better in-field progression-free survival and
overall survival rates (<32 cc vs. ≥32 cc, P < 0.05). No major toxicity was encountered but one patient died with
extrahepatic metastasis and radiation-induced hepatic failure.
Conclusions: SBRT is a promising noninvasive-treatment for small HCC that is ineligible for local treatment or
surgical resection.
Background
Hepatocellular carcinoma (HCC) is one of the most
common malignant diseases [1-3]. Of the current thera-
peutic approaches for HCC, surgical resection and liver
transplantation are used with curative intent for patients
with small HCC [4]. However, the majority of HCC
patients are ineligible for surgery because most have a
cirrhotic liver with poor liver function or tumors are
located in the central segments. Several modalities
including radiofrequency ablation (RFA) and percuta-
neous ethanol injection (PEI) have been used to treat
small HCC, but the optimal treatment remains contro-
versial particularly for cases of small HCC ineligible for
curative therapy.
Cyberknife (Accuracy Inc., Sunnyvale, CA) is a new
stereotactic body radiation therapy (SBRT) that delivers
a high dose of radiation in a short time to well-defined
tumor sites. Cyberknife has been extended to extracra-
nial SBRT applications [5-7] since it was invented for
the treatment of intracranial lesions [8]. However, to
date few studies have reported SBRT including
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especially primary HCC [9-14]. In our previous report
[12], the overall response rate of non-resectable small
HCC and portal vein tumor thrombosis (PVTT) in
advanced HCC was 71.9% for a median follow-up of
10.5 months. This report expands our experience
further, and discusses the long-term effect in primary
HCC of Cyberknife SBRT that was limited to targeting
parenchymal lesions ineligible for local ablation therapy
or surgical resection.
Methods
Patient selection
Sixty-eight HCC patients who underwent Cyberknife
SBRT between March 2004 and May 2007 were initially
considered. The study inclusion criteria for the tumor
were primary HCC targeting parenchymal lesions with-
out extrahepatic metastasis and a tumor volume of ≤
100 cc [9], the presence of technical difficulties with
local therapies such as RFA and PEI, an inoperable state
because of poor liver function or inaccessible site,
patient refusal to undergo surgery, or a viable remnant
portion after previous treatment. All the patients were
judged inoperable or inaccessible by a team consisting
of a hepatobiliary surgeon, radiologist and hepatologist.
Patient criteria were age ≤ 80, an Eastern Co-operative
Group (ECOG) performance score of ≤ 2, preserved
liver function (Child-Pugh class A and B), and no prior
history of radiotherapy. According to the inclusion cri-
teria, 15 patients with targeting the portal vein tumor
thrombosis, nine patients treated for a huge HCC mass
with palliative intent, and two patients with poor liver
function (Child-Pugh class C) were excluded from the
analysis. Thus, 42 HCC patients constituted the study
cohort (Figure 1). HCC was diagnosed histologically or
based on an elevated serum alpha-fetoprotein (AFP)
level (> 400 ng/ml) with typical radiologic findings.
Median follow-up after Cyberknife treatment was 28.7
months (range, 8.4-49.1) and median target tumor
volume was 15.4 cc (range, 3.04-81.82). Written
informed consent was obtained from all patients before
treatment and this study was approved by the review
board of our institution.
Stereotactic body radiation therapy
SBRT was performed using a Cyberknife (Accuracy Inc.)
image-guided radiosurgery system. To obtain radio-
graphic landmarks, we percutaneously implanted four 3
× 1 mm gold seeds under ultrasonographic guidance in
liver parenchyma near the tumor targets. On the follow-
ing day, patients were vacuum immobilized in the
supine position, and computed tomographic (CT)
images were taken in spiral mode with a 2 mm slice
thickness at maximum expiration. We used breath-
holding techniques during Cyberknife treatment as
described in our previous protocol [12].
Gross tumor volume (GTV) was defined as contrast
enhanced tumor volume on CT scans. Clinical tumor
volume (CTV) was defined as a 2 mm margin around
the GTV [15-17] and the planning target volume (PTV)
was defined as a 3 mm margin around the CTV. In gen-
eral, the superior-to-inferior movement was greater than
in the left-to-right and anteroposterior directions. How-
ever, because we could not use 4-dimensional CT scans
and there might be unexpected directional movement
such as torsion or twisting of the tumor, our protocol
defined the same margin as the CTV. The radiation
dose was prescribed at the PTV with an isodose range
of 70-85% (median 80%). The median total dose admi-
nistered was 33 Gy (range, 30-39) delivered in three
fractions on consecutive days. We decided the total dose
mainly based on tumor size and tumor site, considering
dose limitation to nearby normal tissues. We generally
administered 30-36 Gy into the tumor which the
volume was below 30 cc, however if the tumor site was
distant from nearby organs, we administered 39 Gy even
for a small HCC. Conformal shape inverse planning in
the Cyberknife SBRT on-target treatment planning sys-
tem (version 3.3) was used in the study (Figure 2).
Dose limitation to normal tissues
The liver, esophagus, stomach, duodenum, intestine,
kidneys, and spinal cord were contoured during the
planning process and dose-volume histograms (DVH)
were used to ensure that normal tissue tolerances were
not exceeded. We limited the dose to normal tissues as
in our previous protocol [12].
Liver
We evaluated V20 as a predictor for liver damage
accrued from the SBRT in our study: in the a/b ratio of
3, 30-35 Gy with conventional fractionation is equivalent
to a dose of 3 × 6 Gy (total, 18 Gy) to the whole liver.
The V20 was limited so as not to exceed 50% of the
functional whole liver tissue.
Stomach, duodenum and intestine
Because of the lack of clinical data on the effect of very
high fractional doses exceeding 8 Gy, a dose of 7 Gy
was chosen based on the experience in brachytherapy.
Therefore, the maximum dose to the stomach, duode-
num and intestine was limited to below 7 Gy per frac-
tion (total, 21 Gy).
Kidney
In this study, at least two-thirds of the right kidney was
limited to receiving a dose of less than 5 Gy per fraction
(total, 15 Gy). With an a/b r a t i oo f3 ,2 3G yw i t h
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5 Gy (total 15 Gy).
Spinal cord
The maximum dose to the spinal cord was limited to
below 7 Gy per fraction from the linear-quadratic for-
mula of Withers et al. For an a/b ratio of 3, 42 Gy with
conventional fractionation is equivalent to a dose of 3 ×
7 Gy (total, 21 Gy)
Assessment of response and toxicity
Patients underwent dynamic CT scans 1 month after
completion of SBRT, and then tumor response was
checked at 2-3 month intervals. Treatment response and
local recurrence were evaluated using follow-up dynamic
CT scans and serum alpha-fetoprotein (AFP). MRI scans
and/or Positron emission tomography (PET) CT scans
were used to discriminate the vague lesion or response
and evaluate overall response in some cases. In patients
who experienced local recurrence or intrahepatic metas-
tasis after Cyberknife treatment, transarterial chemoem-
bolization (TACE), local ablation therapies, or liver
transplantation were recommended.
In-field and overall tumor responses were defined
principally according to the amended Response Evalua-
tion Criteria in Solid Tumors (RECIST) criteria [18],
taking into account tumor necrosis recognized by non-
enhanced areas. An in-field response was defined as tar-
get lesion response within the irradiated field. Complete
response (CR) was defined as the disappearance of any
intratumoral arterial enhancement in all target lesions.
Partial response (PR) was defined as at least a 30%
decrease in the sum of the diameters of viable (contrast
enhancement in the arterial phase) target lesions, taking
as a reference the baseline sum of the diameters of tar-
get lesions. Progressive disease (PD) was defined as at
least 20% increase in the sum of the diameters of viable
(enhancing) target lesions or the appearance of a new
lesion, and stable disease (SD) was defined as a tumor
status that did not meet the ab o v et h r e er e s p o n s ec r i -
teria. Initial in-field response was evaluated by determin-
ing the maximum reduction rate within 12 months
following Cyberknife treatment. In-field progression was
defined as any progression of the target lesion within
the irradiated field after initial response to Cyberknife
treatment. In-field progression-free survival was calcu-
lated from the date of initial response to the date of in-
field progression. Overall in-field response was defined
as target lesion response at the end of follow-up or the
date of death. Overall response was defined as the
whole body response considering hepatic out-of-field
progression and extrahepatic metastasis in addition to
the hepatic in-field response at the end of follow-up or
the date of death.
Figure 1 Flow of study participants in the study.
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Page 3 of 10Serum AFP response was also evaluated in patients
with a serum AFP level greater than normal before
Cyberknife treatment. Based on percentage changes ver-
sus baseline levels, AFP responses were categorized as
CR (AFP normalization), PR (an AFP reduction of ≥
50%), PD (an AFP increase of ≥ 25%), and SD (an AFP
change that did not meet the above three response
criteria) [19].
Toxicities were assessed using the Radiation Therapy
Oncology Group (RTOG) guidelines [20,21]. Acute toxi-
city was assessed weekly until 90 days post-treatment.
Late toxicity was defined as a toxicity occurring at > 90
days post treatment. For both acute and late toxicities,
grade 3-4 indicates major toxicity.
Statistical analysis
Data are expressed as mean ± SDs, medians (ranges), or
rate. Statistical analyses were performed using SPSS ver-
sion 14.0 for Windows (SPSS Inc., Chicago, IL). Patient
survival was calculated from the date of Cyberknife
treatment until the date of death or last follow-up.
Cumulative survival rates were estimated using the
Kaplan-Meier method. The factors affecting the survival
rate were identified on univariate and multivariate analy-
sis using Cox’s proportional hazard model.
Results
Patient characteristics
Patient baseline characteristics are listed in Table 1. The
patients included 32 men and 10 women aged 60.1 ±
10.9 years. Hepatitis B virus infection was the most
common cause of HCC (69.0%). Ninety percent of
patients were Child-Pugh grade A, and all patients had
an ECOG performance grade of 0 or 1. Fifteen (35.7%)
patients had multifocal tumors, but the target lesion in
these patients was a single viable remnant lesion among
necrotic tumor masses. Eight (19.0%) patients were
treatment naïve, and the others had been treated with
TACE alone or with combined local therapies before
Cyberknife treatment.
Tumor and AFP response
Initial in-field responses and overall in-field responses
are shown in Table 2: CR for 25 patients (59.6%, Figure
3A); PR for 11 patients (26.2%, Figure 3B); and SD for 6
patients (14.3%, Figure 3C). No PD response was
Figure 2 GTV and isodose lines. The dotted red line represents GTV, and the green, yellow, and purple curves the 75, 70 and 10% isodose
lines, respectively. 36 Gy was prescribed on the 75% isodose line. Axial, coronal and sagittal views and dose-volume histogram (DVH) of the
tumor and liver are demonstrated.
Kwon et al. BMC Cancer 2010, 10:475
http://www.biomedcentral.com/1471-2407/10/475
Page 4 of 10observed for an in-field lesion. The mean time to
achieve CR or PR was 5.1 ± 3.7 months. During the fol-
low-up period, in-field progression eventually occurred
in 12 patients (28.6%); all the patients with SD and half
of those with PR for the initial in-field lesions. Thus, all
25 patients with CR as an initial in-field response main-
tained in-field CR throughout follow-up. Apart from
those with in-field CR, 11 patients without in-field pro-
gression developed hepatic out-of-field progression (n =
6), distant metastasis (n = 2) and both (n = 3) during
the follow-up period. In terms of overall response dur-
ing follow-up, 14 patients (33.3%) achieved CR and 28
(66.7%) patients had PD. Sixteen (57.1%) of the 28 PD
patients showed no in-field progression after Cyberknife
treatment but developed out-of-field progressions. Over-
all, hepatic out-of-field progression occurred in 18
patients (42.9%) and distant metastasis developed in 12
patients (28.6%)(Figure 4).
After Cyberknife treatment, 25 patients (59.5%) who
experienced local recurrence or intrahepatic metastasis
underwent salvage therapy such as TACE and/or local
therapy or liver transplantation.
Serum AFP response was assessed in the 22 evaluable
patients with an increased AFP level at baseline (Table
2). Overall, 10 (45.5%) and four (18.2%) of these patients
achieved CR or PR for AFP, respectively. In the follow-
up period, 4 of the 22 patients achieving overall CR
maintained CR for AFP. Of the 18 of the 22 patients
having overall PD, seven showed CR, two PR, one SD
and eight PD for AFP. The seven patients with overall
PD who showed CR for AFP did not develop extrahepa-
tic metastasis, but developed in-field or hepatic out-of-
f i e l dp r o g r e s s i o n .H o w e v e r ,t h e r ew a sn os i g n i f i c a n c e
between other patterns of final AFP response and tumor
progression type.
In-field progression-free survival rates at 6 months, 1
year and 3 years were 83.0%, 72.0% and 68.0%, respec-
tively, with a median progression-free interval of 15.4
months (Figure 5A). In general, greater tumor volume
was associated with more in-field progression. Patients
with a tumor volume of < 32 cc had better in-field
tumor responses and in-field progression-free survival
rates than those with a tumor volume of ≥ 32 cc (P =
0.026, log rank test). The in-field progression free survi-
val rate at 1 year with a tumor volume of < 32 cc was
superior to that with a tumor volume of ≥ 32 cc (81.1%
vs. 38.9%, Figure 5B). The area under the Receiver
Operation Characteristic curve analysis of tumor volume
for predicting in-field progression was 0.676 (P =0 . 0 7 7 )
and a tumor volume of ≥ 32 cc showed a sensitivity of
45.5% and a specificity of 83.3%.
Overall survival rates at 1-year and 3-year after Cyber-
knife treatment were 92.9% and 58.6%, respectively (Fig-
ure 5C). When analyzing the factors affecting survival,
initial in-field response, in-field progression, a tumor
volume of < 32 cc and initial Child-Pugh score were sig-
nificant factors (Table 3). In multivariate analysis, a
tumor volume of < 32 cc and no distant metastasis were
associated with survival.
Adverse events related to treatment
The most common acute events were constitutional
symptoms (34%), elevated liver enzyme (30%), and leu-
copenia (18%), but all improved without requiring speci-
fic management (grade 1 or 2)(Table 4). In one patient
Table 1 Basal characteristics of patients
Patient Characteristics N = 42
Overall median follow up period (months, range) 28.7 (8.4-49.1)
Age (years, mean ± SD) 60.1 ± 10.9
Sex (male/female) 32/10
Cause of HCC (HBV/HCV/Alcohol/Others) 29/7/2/4
ECOG performance (0/1) 41/1
Child-Pugh classification (A/B/C) 38/4/0
AJCC stage (I/II/IIIa/IV) 23/16/3/0
Median tumor volume (cc, range) 15.4 (3.04-81.82)
Tumor number (solitary/multifocal) 27/15
Initial median AFP (ng/dl, range) 13.9 (1.0-798.8)
Previous therapy
No treatment 8
TACE alone 16
TACE combined with locoregional therapies 16 (PEI 13, RFA 3)
TACE combined with surgical resection 2
Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV,
hepatitis C virus; ECOG performance, Eastern Co-operative Group
performance; AFP, alfa-fetoprotein; TACE, transarterial chemoembolization; PEI,
percutaneous ethanol injection; RFA, radiofrequency ablation
Table 2 Tumor and AFP response
Response In-field response Overall In-field response Overall response AFP response
Initial response ! Progression
CR 25 (59.6) 0 25 (59.6) 14 (33.3) 10 (45.5)
PR 11 (26.2) 6 (54.5) 5 (11.9) 0 4 (18.2)
SD 6 (14.3) 6 (50.0) 0 0 4 (18.2)
PD 0 0 12 (28.6) 28 (66.7) 4 (18.2)
Total 42 (100) 12 (28.6) 42 (100) 42 (100) 22
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
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Page 5 of 10there was a targeting error because the true lesion
located in the hepatic angle was moved by spontaneous
large bowel movement. This patient was retreated 1
week after initial Cyberknife treatment. The missed tar-
get lesion showed necrosis on CT scan after 1 month,
but no complications developed. One male patient
experienced a major late toxicity (grade 4). This patient
showed progressive elevation of total bilirubin and alka-
line phosphatase without liver enzyme elevation com-
bined with cancer recurrence and bone metastasis and
died from hepatic failure 20 months after Cyberknife
treatment. He had a tumor volume of 35.1 cc for Cyber-
knife treatment, and 30 Gy had been prescribed.
Discussion
The results of this study show excellent in-field
responses to Cyberknife SBRT in HCC within tumors <
100 cc in volume that are ineligible for local ablation
therapies or surgical resection. Furthermore, all patients
that initially achieved CR for in-field lesions experienced
no in-field progression during the follow-up period.
Surgical resection is best indicated for patients with a
single tumor and well-preserved liver function, and such
p a t i e n t sm a ya c h i e v ea5 - y e a rs u r v i v a lr a t eo f6 0 - 7 0 %
[22,23]. In the present study, the 3-year survival rate for
Cyberknife SBRT was 58.6%, which was slightly lower
than for surgical resection. In view of the large propor-
tion of multifocal tumors in our study population and
the difficult tumor sites for operation, we find this survi-
val rate acceptable [4,24]. Other local treatment meth-
ods, especially RFA, are emerging as alternative curative
options for patients unsuitable for surgery or liver trans-
plantation [4]. Complete tumor necrosis by RFA was
pathologically shown by 83% of tumors < 3 cm [25], but
proximity of lesions to the gall bladder or main vessels,
a sub-diaphragmatic location, or the presence of a
non-echogenic lesion present major problems for the
use of RFA [26]. Although radiotherapy alone or in
Figure 3 In-field tumor response after Cyberknife treatment. A) A case of complete response. B) A case of partial response. C) A case of
stable disease. (Arrow: target lesion, arrowhead: intrahepatic metastasis)
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Page 6 of 10combination with TACE has become a potential treat-
ment option for advanced HCC, it is not considered as
first-line treatment for small HCC [27,28]. Doses of 30-
35 Gy with conventional fractionation are often consid-
ered to be the limit of liver tolerance. However, the role
of radiotherapy for the treatment of small HCC or por-
tal vein thrombosis has recently been emphasized in the
context of the development of SBRT. This is because
the radiation dose delivered by SBRT rapidly falls off at
the periphery of target lesions, which enables the
Figure 4 Pattern of disease recurrence. CR; complete response, PD; progressive disease
Figure 5 In-field progression-free survival rates and overall survival rates. A) In-field progression-free survival rates. B) Patients with a tumor
volume of < 32 cc had longer in-field progression-free survival rates than those with a tumor volume of ≥ 32 cc (P = 0.026 by log rank test). C)
Overall survival rates.
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Page 7 of 10accurate delivery of high doses of radiation to a specified
lesion with hypofractionation as opposed to traditional
protracted treatment courses over several weeks. We did
not intend to compare RFA/surgical resection and SBRT
in small HCC, but we suggest that SBRT is an alterna-
tive option in case of ineligible for the former treatment.
We reviewed the reports of SBRT including more than
15 cases of its use for primary HCC (Table 5) [9,11].
Blomgren et al. first reported the use of hypofractio-
nated SBRT for the treatment of extracranial malignan-
cies [29]. Although several reports on hypofractionated
SBRT applied to intrahepatic tumors, such as cholangio-
carcinoma and metastatic tumors were subsequently
published [9-11,15-17,30-32], little has been published
on its performance in primary HCC. In the studies
shown in table 5, median follow-up periods ranged from
17.6 to 28.7 months, median tumor volume ranged from
13.6 to 173 cc and local control rates were 65%-100% at
1-2 years [9,11]. Local failure was usually defined as
recurrence of the target tumor, the demonstration of
new enhancement, or RECIST progressive disease,
although definitions of local control vary between the
studies. Takeda et al. [9] reported the highest local
control rate to date at > 90%, which is probably attribu-
table to a tumor volume of < 100 cc and the fact that
14 of their 16 patients underwent combined TACE 2
weeks prior to SBRT. Furthermore, in that study [9] SD
lesions might have been included in the local control
group, because RECIST responses were not shown. Tse
et al. [11] reported the lowest local control rate, 65% at
1 year, presumably, because tumor volumes were large
(median 170 cc). Although Wulf et al. [16] reported a
local control rate of 100% for a median tumor volume
of 114 cc (range, 14-516), the overall survival rate was
only 20% at 2 years because of intrahepatic metastasis
and progression. In contrast, we did not achieve out-
standing local control rates (in-field progression-free
rate) at 1 and 2 years, but the overall survival rates at 1
and 3 years, 92.9% and 58.6%, were better. In addition,
it was interesting to find that patients who achieved
initial in-field CR maintained this status throughout fol-
low-up, which suggests that initial in-field response and
in-field progression are important overall survival indi-
cators. However, we should note the 11 patients in the
initial in-field CR developed hepatic out-of-field progres-
sion and distant metastasis without in-field progression.
Because SBRT is a local treatment and a tumor volume
of < 32 cc and distant metastasis were significant factors
for survival, regular monitoring for target lesion and dis-
tant metastasis is essential.
The use of Cyberknife SBRT as a method for hypo-
fractionated SBRT to treat primary HCC is an important
aspect of our study. A phase I dose escalation trial of
Cyberknife SBRT in liver tumors was published in
abstract form in the American Society of Clinical Oncol-
ogy (ASCO) in 2006 and 2007 [13,14] and our prelimin-
ary findings were reported in 2008 [12]. The 2006
ASCO report of 12 unresectable primary or metastatic
liver tumors with a mean volume of 27.1 cc and a med-
ian follow-up of 6 months demonstrated an interval
decrease in size for six lesions and stable disease for
three lesions. According to the ASCO 2007 report,
Cyberknife SBRT-treated primary liver or metastatic
tumors achieved 24% CR and 40% PR over a median fol-
low-up of 7 months. These outcomes are better than
those mentioned in prior reports for other hypofractio-
nated SBRT using the conventional LINAC. In our pre-
vious study [12], CR and PR for the small HCC group
that was not the PVTT target group were 26.1% and
56.3%, respectively. Our study shows better responses
(CR 59.6% and PR 25.5%) than the ASCO reports
[13,14], although we analyzed only primary HCCs of ≤
100 cc. The advantage of the present study is that
Cyberknife SBRT was used to treat a large number of
primary HCC and patients were followed over a rela-
tively long follow-up period.
Table 3 Factors identified on univariate and multivariate
analysis as influencing the survival
Univariate
analysis
Multivariate analysis
P Hazard ratio (95%
Confidence Interval)
P
Initial In-field response 0.003
In-field progression 0.006
Hepatic out-field
recurrence
0.106
Distant metastasis 0.167 15.495 (1.298-184.896) 0.030
Tumor stage 0.218
Initial tumor volume
32 cc (< vs. ≥)
0.005 6.328 (1.126-35.574) 0.036
Child-Pugh
classification score
0.023
Age 0.822
Table 4 Adverse events related to treatment
Toxicity Acute (%) Late (%)
grade Grade 1 Grade 2 Grade 4
Constitutional symptoms 15 0 0
Leukopenia 5 3 0
Elevated liver enzyme 5 8 0
Elevated bilirubin and
alkaline phosphatase
010
Liver failure 0 0 1
Other (target error) 0 1 0
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there was no report identifying the safe dose. In terms of
toxicity, the present study shows that Cyberknife SBRT is
feasible and safe in primary HCC, which is consistent
with the findings of a previous phase I study [13,14] and
our previous study [12]. One of our patients died as a
result of radiation-induced hepatic failure 20 months
after Cyberknife treatment, but he also experienced com-
bined tumor progression and metastasis. Takeda et al.
and Tse et al. also reported no serious SBRT-related toxi-
cities [9,11]. A targeting error suggests the importance of
tumor location, particularly in the hepatic angle or near
the beating heart, and of control breath holding. We con-
toured the liver, stomach, duodenum, intestine, kidney,
and spinal cords during the planning process and used
D V Ht oe n s u r et h a tn o r m a lt i s s u et o l e r a n c e sw e r en o t
exceeded. We plan to escalate the total dose 42-45 Gy in
three fractionation in case of favorable tumor sites, taking
into consideration the limitation dose to normal tissues.
Conclusions
In the present study, excellent in-field responses were
obtained for Cyberknife SBRT in HCC. Notably, all
patients who initially achieved CR for in-field lesions
maintained in-field CR during the follow-up period
(median 28.7 months). Furthermore, this study shows
that Cyberknife SBRT is a feasible, effective treatment
for primary HCC, and suggests that Cyberknife SBRT be
considered a promising noninvasive modality when
small HCC of < 32 cc is inappropriate for surgical resec-
tion or ablation therapy. Further study is required to
define the effects of administered radiation dose and
fractionation, and to determine toxicities in selected
patients with small HCC.
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